Grunewald S, Politz O, Bender S, Heroult M, et al. Rogaratinib: A potent and selective pan-FGFR inhibitor with broad antitumor activity in FGFR-overexpressing preclinical cancer models. Int J Cancer 2019;145:1346-1357.
PMID: 30807645